"I wasn’t at Bayer at the time, so I don’t want to speculate too much, but I think there was concern that diabetes and urine chemistry were niche businesses that might not be defensible. While they were very profitable and growing nicely, they were viewed as a leverage assets to get into diagnostics in a much broader way...."

"I hope that we will be able to grow this business double digits with the mix of businesses we have. Almost half of our mix is in diabetes, which is helpful in sustaining a higher-than-average profit..."

http://www.casebauer.com/publications/library/p012.htm